Treatment for Andropause (Late-Onset Hypogonadism)
Testosterone replacement therapy (TRT) is recommended for men with symptomatic hypogonadism to improve sexual function, quality of life, muscle mass, strength, and bone mineral density, but should not be used in eugonadal men or those with contraindications. 1
Diagnosis and Assessment
- Diagnosis of hypogonadism should only be made in men with consistent symptoms and unequivocally low serum testosterone levels 1
- Laboratory confirmation requires:
- Clinical evaluation should include:
Treatment Recommendations
First-line Treatment: Lifestyle Modifications
- Weight loss through low-calorie diets can reverse obesity-associated secondary hypogonadism 1
- Physical activity shows benefits with results correlating to exercise duration and weight loss 1
- These interventions may increase testosterone levels by 1-2 nmol/L 1
Pharmacological Treatment
Testosterone replacement therapy is indicated for men with:
Formulation options:
Target testosterone levels:
Contraindications to Testosterone Therapy
- Absolute contraindications:
- Active or treated male breast cancer 1
- Planning fertility in the near term 1, 2
- Prostate cancer 2
- PSA >4 ng/mL or >3 ng/mL in high-risk men without urological evaluation 2
- Elevated hematocrit 2
- Untreated severe obstructive sleep apnea 2
- Severe lower urinary tract symptoms 2
- Uncontrolled heart failure 2
- Recent myocardial infarction or stroke (within 6 months) 2
Monitoring During Treatment
- Regular follow-up with standardized monitoring plan:
Expected Benefits and Limitations
Benefits of testosterone therapy:
Limited or no benefit for:
Important Considerations
- Testosterone therapy should not be used in eugonadal men 1
- Fertility concerns must be addressed before initiating therapy 1
- Testosterone testing should be avoided during acute illness 1
- Long-term efficacy and safety data are limited, particularly for cardiovascular outcomes and prostate cancer risk 1
- Combining lifestyle modifications with TRT may yield better outcomes in symptomatic patients 1